Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2024 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Trevi Therapeutics First Quarter 2024 Earnings Conference Call. At this time, all participants will be in a listen-only mode.
Trevi Therapeutics Inc. (TRVI)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Rubric Capital Management David Rosen | 5,564,123 | $19,196,224 | -3% | 0.56% |
| 2. | Viking Global Andreas Halvorsen | 4,400,000 | $15,180,000 | 0.05% | |
| 3. | Opaleye Management James A. Silverman | 2,645,000 | $9,125,250 | +5% | 1.98% |
| 4. | Logos Capital Arsani William | 2,200,000 | $7,590,000 | 0.61% | |
| 5. | BioImpact Capital Mpm Capital | 1,340,960 | $4,626,312 | 0.74% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.90 | 948,948 | Large Shareholder | 948,948 | 2022-04-11 | Filing | |
| $1.90 | 2,631,578 | Large Shareholder | 10,421,428 | 2022-04-11 | Filing | |
| $1.90 | 948,948 | Large Shareholder | 948,948 | 2022-04-11 | Filing | |
| $1.90 | 2,631,578 | Large Shareholder | 10,421,428 | 2022-04-11 | Filing | |
| $1.90 | 948,948 | Large Shareholder | 948,948 | 2022-04-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.55 | 53,368 | 214,433 | 2024-05-29 | Filing | ||
| $2.64 | 4,350 | 53,279 | 2024-05-22 | Filing | ||
| $2.86 | 25,037 | 213,313 | 2024-05-20 | Filing | ||
| $2.90 | 4,578 | 213,313 | 2024-05-10 | Filing | ||
| $2.02 | 785 | Officer | 35,901 | 2023-10-11 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 11,370,376 | $15,236,304 | 1.01% | |
| 2. | 7,381,090 | $9,890,661 | 0.52% | |
| 3. | 3,422,397 | $4,586,012 | 0.31% | |
| 4. | 2,319,716 | $3,108,419 | 0% | |
| 5. | 2,243,399 | $3,006,154 | 0% |
News See All
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2023 Earnings Call Transcript
Trevi Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.08, expectations were $-0.1.
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q3 2023 Earnings Call Transcript
Operator: Good afternoon and welcome to the Trevi Therapeutics Q3 2023 Earnings Conference Call. At this time all participants will be in a listen-only mode.
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q2 2023 Earnings Call Transcript
Operator: Good afternoon and welcome to the Trevi Therapeutics’ Second Quarter 2023 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2023 Earnings Call Transcript
Operator: Good afternoon and welcome to the Trevi Therapeutics’ Q1 2023 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2022 Earnings Call Transcript
Operator: Good afternoon and welcome to the Trevi Therapeutics Q4 and Year-End 2022 Earnings Conference Call. Please note this event is being recorded.
Billionaire Hedge Funds
